Results 31 to 40 of about 53,090 (292)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells

Translational Oncology, 2023
Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar ...
Shang-Ju Wu, Chien-Ting Lin, Cheng Hao Liao, Chun-Ming Lin   +3 more
doaj   +1 more source

Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells [PDF]

The Journal of Immunology, 2010
Abstract T cells gene-modified to express chimeric Ag receptors (CARs) have shown potent antitumor activity in vivo and are in clinical trials at locations worldwide. However, CAR activity has been investigated in mouse models in which Ag expression is restricted to the tumor.
Cheadle, Eleanor J., Hawkins, Robert E., Batha, Hayley, O'Neill, Allison L., Dovedi, Simon J., Gilham, David E.   +5 more
openaire   +2 more sources

Mesenchymal stem cells promote leukaemic cells aberrant phenotype from B-cell acute lymphoblastic leukaemia

Hematology/Oncology and Stem Cell Therapy, 2013
BACKGROUND AND OBJECTIVES: The role of bone marrow-mesenchymal stem cells (BM-MSC) in leukae-mic cell control is controversial. The purpose of this work was to evaluate BM-MSC role regarding the viability, proliferation and immunophenotype of normal B ...
Viviana M Rodríguez-Pardo, José A Aristizabal, Diana Jaimes, Sandra M Quijano, Iliana de los Reyes, María Victoria Herrera, Julio Solano, Jean Paul Vernot   +7 more
doaj   +1 more source

Acute myeloid leukemia: Comparing French–American–British classification with immunophenotype and cytogenetics

BLDE University Journal of Health Sciences, 2022
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease as it affects multiple lineages of hematopoietic cells. AIMS AND OBJECTIVES: This study aims to (1) evaluate the immunophenotypic findings of AML patients, (2) correlate the ...
Mekhala Rao, Girish Kamat, Deepak Goni, Girish Balikai   +3 more
doaj   +1 more source

Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. [PDF]

, 2011
BACKGROUND: Offspring of women with schistosomiasis may exhibit immune responsiveness to schistosomes due to in utero sensitisation or trans-placental transfer of antibodies.
Webb, Emily L, Emily L Webb, Dunne, David W, Dunne, David W., Tweyongyere, Robert, Mawa, Patrice A, Birgitte J Vennervald, David W Dunne, Jones, Frances M., Webb, Emily L., Elliott, Alison M., Patrice A Mawa, Vennervald, Birgitte J, Frances M Jones, Stephen Cose, Kihembo, Macklyn, Alison M Elliott, Cose, Stephen, Macklyn Kihembo, Elliott, Alison M, Robert Tweyongyere, Jones, Frances M, Mawa, Patrice A.   +22 more
core   +1 more source

Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease

, 2021
CD19-directed treatment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry (MFC) application for minimal/measurable residual disease (MRD) assessment in ...
Semchenkova A., Larin S., Novichkova G., Kashpor S., Brilliantova V., Molostova O., Olshanskaya Y., Miakova N., Maschan M., Mikhailova E., Raykina E., Popov A. M., Zakharova E., Khismatullina R., Zerkalenkova E., Diakonova Y., Zhogov V., Illarionova O., Shelikhova L., Buldini B., Zangrando A., Bocharova N.   +21 more
core   +1 more source

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy

OncoImmunology, 2021
Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression ...
Patrick Schreiner, Mireya Paulina Velasquez, Stephen Gottschalk, Jinghui Zhang, Yiping Fan   +4 more
doaj   +1 more source

Chimeric antigen receptor–modified T cells: CD19 and the road beyond [PDF]

Blood, 2018
Abstract The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients
Alexander I. Salter, Margot J. Pont, Stanley R. Riddell   +2 more
openaire   +2 more sources

Targeting antigen to CD19 on B cells efficiently activates T cells [PDF]

International Immunology, 2005
CD19 is a B cell-surface molecule that participates as an important regulatory signaling complex for antigen bound at the surface by Ig. Triggering of CD19 through its linkage with CD21 amplifies signals transduced through the Src family kinases and modulates B cell differentiation in response to antigen.
Jun, Yan, Martin J, Wolff, Julia, Unternaehrer, Ira, Mellman, Mark J, Mamula   +4 more
openaire   +2 more sources

Distinct and shared B cell responses of tuberculosis patients and their household contacts

PLoS ONE, 2022
This study was aimed at identifying the B cell responses which could distinguish between ‘latent tuberculosis infection (LTBI)’ and active TB disease. Study subjects were smear-positive TB patients (n = 54) and their disease-free household contacts (HHCs,
Komal Singh, Rajesh Kumar, Fareha Umam, Prerna Kapoor, Sudhir Sinha, Amita Aggarwal   +5 more
doaj